[ad_1]
The latest news is that Samantha Ruth Prabhu is going to South Korea for myositis treatment. This is reported by India Glitz. It seems that Samantha Ruth Prabhu has decided to go to the country for advanced treatment of myositis. While she clarified that the disorder is not life-threatening, she admitted that she struggles with her day-to-day life. A source told India Glitz that Samantha Ruth Prabhu intends to get back to full fitness in Korea and return for the shoot of Vijay Deverakonda’s Kushi. She is currently basking in Yashoda’s success.
Samantha Ruth Prabhu suffers from myositis, which is a health problem that affects the muscles and joints. It causes inflammation. The actress shared that the last few months have not been easy. She was also treated in the USA. South Korea is closer to India than the US, also the medical care is top notch which means it is a good choice. In India, treatment for autoimmune problems is available only in selected places, making it difficult. South Korea may also offer the actress the privacy she needs during her recovery and recovery. The country has exceptional medical services for the elite.
Samantha Ruth Prabhu has been constantly in the news since her divorce with Naga Chaitanya. Naga Chaitanya was reported to have spoken to her on the phone after her myositis diagnosis came out. Samantha Ruth Prabhu said she has been in a vulnerable space since her diagnosis came out. The actress also had to train for the Hindi remake of The Citadel with Varun Dhawan. But that has been put on hold due to her diagnosis. From Jr NTR to Chiranjeevi, everyone is rooting for the actress, this is her fight.
Stay tuned to BollywoodLife for the latest news and updates from Bollywood, Hollywood, South, TV and web series.
Click to join us on Facebook, TwitterYouTube and Instagram.
Also follow us on Facebook Messenger for the latest updates.
(function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.src="https://connect.facebook.net/en_US/sdk/xfbml.customerchat.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));
// jQuery(window).scroll(function(){ // if (isInView(jQuery('#live-blog-update'))){ // getMoreBlogEntries(); // } // });
$(document).ready(function(){ $('#commentbtn').on("click",function(){ (function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.src="https://connect.facebook.net/en_US/sdk.js#xfbml=1&version=v3.0&appId=179720252061082&autoLogAppEvents=1"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));
$(".cmntbox").toggle();
});
});
[ad_2]
Source link